Results 301 to 310 of about 266,823 (339)

ANTI-VEGF TREATMENT Safety of intravitreal anti-VEGFs during pregnancy is unclear

, 2012
Georgalas, Ilias, Petrou, Petros, Koutsandrea, Chrysanthi   +2 more
openaire   +1 more source

Identifying predictors associated with diabetic macular oedema progression in a Maltese cohort using anti-VEGF naïve patients treated with intra-vitreal bevacizumab injections

, 2019
Francis Carbonaro, Alastair David Bezzina   +1 more
openalex   +1 more source

Erratum in: Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema. [PDF]

Invest Ophthalmol Vis Sci
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-VEGF and Retinal Dystrophies

Current Drug Targets, 2020
The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected
Battaglia Parodi Maurizio, Iacono Pierluigi, Da Pozzo Stefano   +2 more
openaire   +3 more sources

Anti-VEGF

2010
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
BANDELLO , FRANCESCO, Battaglia Parodi M.   +1 more
openaire   +3 more sources

Resistance to Anti-VEGF Agents

Current Pharmaceutical Design, 2004
The number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment.
Ton, N. C., Jayson, G. C.
openaire   +2 more sources

Anti-VEGF therapy for diabetic retinopathy

Vestnik oftal'mologii, 2021
Diabetic retinopathy (DR) is one of the most severe complications of diabetes mellitus, its treatment involves specialists of different areas - endocrinologists, diabetes specialists, therapists, cardiologists, surgeons, anesthesiologists etc. For ophthalmologists the objective is to diagnose ocular pathological changes associated with diabetes ...
E S, Chekhonin, R R, Fayzrakhmanov, A V, Sukhanova, E D, Bosov   +3 more
openaire   +2 more sources

Anti-VEGF therapy for glaucoma

Current Opinion in Ophthalmology, 2010
The role of antivascular endothelial growth factor (anti-VEGF) agents in treating various ophthalmic diseases is currently being investigated. There have been many advances in the understanding of how anti-VEGF agents work and speculation on when to implement them clinically for neovascular glaucoma.
Michael B, Horsley, Malik Y, Kahook
openaire   +2 more sources